Antibody-drug complex containing toll-like receptor 7 / 8 dual agonist compound
JPWO2024095964A5Pending Publication Date: 2026-06-03
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Filing Date
- 2023-10-30
- Publication Date
- 2026-06-03
AI Technical Summary
Technical Problem
Current cancer therapies lack effective targeting of CLDN6-expressing cancers, such as ovarian, testicular, and lung cancers, as there are no reported antibody-drug conjugates containing TLR7/8 dual agonist compounds.
Method used
Development of an antibody-drug conjugate comprising a TLR7/8 dual agonist compound and an anti-CLDN6 antibody, which binds to CLDN6 on cancer cells, inducing TNF-α and INF-γ production and exhibiting in vivo antitumor effects.
Benefits of technology
The antibody-drug conjugate effectively targets CLDN6-expressing cancers, inducing cytokine production and demonstrating antitumor activity, providing a novel therapeutic approach for ovarian, testicular, and lung cancers.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2024095964000001 
Figure 2024095964000002 
Figure 2024095964000003
Abstract
The present invention addresses the problem of developing an antibody-drug complex containing a TLR7 / 8 dual agonist compound or a salt thereof to provide a pharmaceutical composition used for the prevention or treatment of various types of cancer. The present inventors have discovered a compound having a TLR7 / 8 dual agonistic activity or a salt thereof, and have studied on an antibody-drug complex that can be used as an active ingredient for a pharmaceutical composition for the prevention or treatment of various types of cancer. As a result, it is found that the antibody-drug complex of the present invention or a salt thereof has a TNF-α- and INF-γ-producing effect and an in vivo anti-tumor effect and can be used for the prevention or treatment of cancer. Furthermore, an anti-CLDN6 antibody is also discovered, which is used for the antibody-drug complex of the present invention or a salt thereof. The antibody-drug complex containing a TLR7 / 8 dual agonist compound according to the present invention or a salt thereof, and a compound represented by formula (II) according to the present invention or a salt thereof have a TNF-α- and INF-γ-producing effect and an in vivo anti-tumor effect and are expected as a prophylactic or therapeutic agent for cancer.
Need to check novelty before this filing date? Find Prior Art